In the April–June 2015 edition of Corporate Disputes, Dr. Gregory Bell and Professor Iain Cockburn discuss damages in the pharmaceutical and biotech sector . To read more, click on the link below.
Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.